Business
Teknova Reports First Quarter 2025 Financial Results
First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnosti
About this update from Alpha Teknova, Inc.
[{"type":"image","alt":"Alpha Teknova, Inc.","displaySize":"","headline":null,"caption":"Alpha Teknova, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/df2ff657ca48a3da043108ece262fc87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HeH6DhTJ3_7i2OIdUQNQNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/df2ff657ca48a3da043108ece262fc87","width":300,"height":58}},"lazy":false},{"type":"text","content":"First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million","length":242,"tagName":"p"},{"type":"text","content":"HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2025.","length":350,"tagName":"p"},{"type":"text","content":"“We delivered strong financial and operational results in the first quarter,” said Stephen Gunstream, President and Chief Executive Officer at Teknova. “Our ability to drive organic growth in such a highly uncertain macroenvironment is a testament to the criticality of our product portfolio and diversity of our customer base. We remain confident in our long-term outlook, particularly as our clinical customers advance their therapies towards commercialization.”","length":464,"tagName":"p"},{"type":"text","content":"Matt Lowell, Teknova’s Chief Financial Officer, added, “We delivered strong financial results in the first quarter 2025 compared to 2024, including 5% revenue growth and significant improvements in adjusted EBITDA and free cash outflow. We believe the Company is well positioned to maintain its momentum. We therefore reiterate our 2025 revenue guidance of $39-42 million and continue to anticipate full-year free cash outflow of less than $12 million,” he explained.","length":472,"tagName":"p"},{"type":"text","content":"Corporate and Financial Updates","length":31,"tagName":"p"},{"type":"list","items":[{"val":[...